Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_4
1
20%
Ph phase_3
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)

Trials by Status

terminated120%
unknown120%
completed360%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_3

A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis

NCT01995201
completed

Ultrasound Utility in Routine Clinical Practise

NCT03124225
terminatedphase_4

A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis

NCT01251120
completed

Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudy

NCT00116714
unknownphase_2

New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis

NCT00244179

Clinical Trials (5)

Showing 5 of 5 trials
NCT01995201Phase 3

A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis

Completed
NCT03124225

Ultrasound Utility in Routine Clinical Practise

Completed
NCT01251120Phase 4

A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis

Terminated
NCT00116714

Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudy

Completed
NCT00244179Phase 2

New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5